Vitamin B1 (Thiamine)
INCI: Thiamine Mononitrate
Thiamine mononitrate is a stable, water-soluble form of vitamin B1 used in gummy and sachet supplements. It supports normal energy metabolism, nervous system function, psychological function, and heart function. Under applicable claims framework, these are the authorised health claims for thiamine.
- energy metabolism
- nervous system
- heart function
At a glance
- Definition
- Thiamine mononitrate is a stable, water-soluble form of vitamin B1 used in gummy and sachet supplements. It supports normal energy metabolism, nervous system function, psychological function, and heart function. Under applicable claims framework, these are the authorised health claims for thiamine.
- Authorised wording (summary)
- 2 authorised statements — see "US structure-function statements" below.
- Common gummy positionings
- Energy and vitality
- Daily wellness
- Sports recovery
- Healthy ageing
- Cognitive function
- Format suitability
- Suitable for gummy formats — confirmed per project.
What it is
Thiamine mononitrate is a synthetic, highly stable form of vitamin B1, an essential water-soluble vitamin that the body cannot produce on its own. It is one of the most cost-effective and commercially established B-vitamin actives used in gummy and sachet manufacturing across the EU, UK, and US markets.
Brands use thiamine mononitrate to build products positioned around energy metabolism, nervous system support, and daily wellness. Its neutral taste, heat stability, and low cost make it a practical choice for gummy formulations, particularly in multi-vitamin blends and sports recovery ranges.
Origin and history
Thiamine was first isolated in 1926 by Dutch chemists Barend Coenraad Petrus Jansen and Willem Frederik Donath, who extracted it from rice bran. The structure was determined in 1934, and synthetic production began shortly after. Thiamine mononitrate was developed as a more stable salt form suitable for dry processing and long shelf-life applications.
Today, thiamine mononitrate is produced industrially through chemical synthesis. It is the preferred form for dry powder blends and gummy manufacturing due to its superior stability compared to thiamine hydrochloride, which is more hygroscopic. The mononitrate salt is also less reactive with other ingredients during processing.
Scientific overview
Thiamine acts as a coenzyme in the form of thiamine pyrophosphate (TPP), which is essential for carbohydrate metabolism and the production of adenosine triphosphate (ATP). It plays a critical role in the conversion of glucose into energy, particularly in tissues with high energy demands such as the brain, heart, and skeletal muscle. Thiamine also contributes to the synthesis of neurotransmitters and myelin sheath maintenance.
Bioavailability of thiamine mononitrate is high, with absorption occurring primarily in the small intestine via both active transport at low doses and passive diffusion at higher doses. The mononitrate form is non-hygroscopic and chemically stable, making it suitable for gummy manufacturing where moisture and heat exposure are factors.
From a manufacturing perspective, thiamine mononitrate is heat-stable and soluble in gummy matrices. It does not require encapsulation or special handling. The cost-per-mg is low, making it an economical choice for multi-vitamin blends. Thiamine hydrochloride is an alternative form but is more hygroscopic and less stable in humid environments.
Why brands use Vitamin B1 (Thiamine) in gummies
Thiamine mononitrate is one of the most familiar and commercially understood gummy actives across EU and US markets. Brands position it primarily for energy metabolism and nervous system support, often in combination with other B-vitamins such as B6, B12, and niacin. It is a staple ingredient in daily wellness, sports recovery, and healthy ageing ranges.
From a formulation perspective, thiamine mononitrate offers several advantages. It is heat-stable, soluble in gummy bases, and neutral-tasting at typical supplement doses. The low cost per mg allows brands to include meaningful doses without significantly impacting the overall bill of materials. Standard gummy processing applies, and no special handling is required.
For pack copy, brands may use the EFSA-authorised claims verbatim: "contributes to normal energy-yielding metabolism" and "contributes to normal functioning of the nervous system." No disease claims are permitted. Certification status (vegan, kosher, halal) and shelf-life claims are confirmed per project and batch documentation. DAT reviews all claim wording and compliance requirements per project.
Gummy formulation notes
Verified formulation reference. Final formulation, dose and on-pack copy are confirmed per project.
- Gummy fit
- Good
- Heat stable
- Yes
- Soluble in matrix
- Yes
- Cost tier
- Low
Forms available
- Thiamine mononitrate, Thiamine hydrochloride (HCl)
Dosage reference
reference-intake target reviewed per market for thiamine is 1.1 mg. Brand positioning typically ranges from 1.1 mg to 50 mg per serving. Claim thresholds follow EFSA-authorised wording at any dose providing at least 15% NRV per 100 g or 100 ml for labelling purposes.
Taste & sensory
Neutral to mild taste at supplement doses.
Manufacturing notes
No specific formulation notes. Standard processing applies.
US structure-function statements
- Thiamine helps convert food into energy.Structure-function (DSHEA)
- Thiamine supports normal nervous system function.Structure-function (DSHEA)
Structure-function statements must appear with the FDA disclaimer in the same field of vision on the label. % Daily Value (DV) based on FDA 21 CFR 101.9.
Wording to avoid on pack copy
- No disease claims — this product is not intended to diagnose, treat, cure, or prevent any disease.
- Structure-function claims must be accompanied by the FDA disclaimer: 'These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.'
- No certification promises on pack until confirmed per project and batch documentation.
- No guaranteed shelf-life on pack until confirmed with stability data.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Structure-function claims are permitted under DSHEA (21 USC §343(r)(6)). Daily Value (DV) for thiamine is 1.2 mg under FDA 21 CFR 101.9.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Studies & evidence
External peer-reviewed sources and regulatory opinions. Citations only — DAT does not endorse the publishers.
DiNicolantonio JJ, Niazi AK, Lavie CJ, O'Keefe JH·Progress in Cardiovascular Diseases·2018
Calderón-Ospina CA, Nava-Mesa MO·Nutrients·2020
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)·EFSA Journal·2009
Bettendorff L, Wins P·Journal of Neurochemistry·2013
Manzetti S, Zhang J, van der Spoel D·Biochemistry·2014
Sica DA·Journal of Clinical Hypertension·2007
Synergies & conflicts
Pairs well with
Synergy data needs review.
Care when combining with
Conflict data needs review.
Build a formula with Vitamin B1 (Thiamine)
Hand the brief over to the DAT portal. The wizard pre-fills the ingredient, target market, and route so the project review starts with the right context.
References
- Thiamine and cardiovascular disease: A literature review — DiNicolantonio JJ, Niazi AK, Lavie CJ, O'Keefe JH, Progress in Cardiovascular Diseases, 2018.
- Thiamine in the treatment of neurological disorders — Calderón-Ospina CA, Nava-Mesa MO, Nutrients, 2020.
- Scientific Opinion on the substantiation of health claims related to thiamine — EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), EFSA Journal, 2009.
- Thiamine and the nervous system: A review — Bettendorff L, Wins P, Journal of Neurochemistry, 2013.
- Vitamin B1 (thiamine) metabolism and its role in energy metabolism — Manzetti S, Zhang J, van der Spoel D, Biochemistry, 2014.
- Thiamine deficiency and its role in cardiovascular disease — Sica DA, Journal of Clinical Hypertension, 2007.